Jiangsu Hengrui Pharmaceuticals and Kailera Therapeutics announced positive results from a Phase II trial of their GLP-1/GIP receptor dual agonist HRS9531 for obesity treatment.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing
Hengrui and Kailera report best-in-class data from Phase II GLP-1/GIP trial
